Next Article in Journal
Variations in Morpho-Cultural Characteristics and Pathogenicity of Fusarium moniliforme of Bakanae Disease of Rice and Evaluation of In Vitro Growth Suppression Potential of Some Bioagents
Previous Article in Journal
The Effect of Cell-Free Nontuberculous Mycobacterium Supernatants on Antibiotic Resistance and Biofilm Formation of Opportunistic Pathogens
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Bacteria
Volume 2
Issue 4
10.3390/bacteria2040014
bacteria-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Bacteremia Following Alkalihalobacillus clausii (Formerly Bacillus clausii) Administration in Immunosuppressed Adults: A Case Series

by
José Pablo Díaz-Madriz
1,2,3,
Esteban Zavaleta-Monestel
1,2,*,
Carolina Rojas-Chinchilla
1,3,
Sebastián Arguedas-Chacón
1,3,
Bruno Serrano-Arias
1,
Mery Alejandra Ferreto-Meza
2,
Betzy María Romero-Chavarría
2,
Priscila Zumbado-Amerling
2,
Ana Fernanda Vásquez-Mendoza
3,4,
Karla Sofia Gutiérrez-González
4 and
César Rodríguez
5,6
1
Pharmacy Department, Hospital Clínica Bíblica, San José 10104, Costa Rica
2
Faculty of Pharmacy, Universidad de Ciencias Médicas, San José 10108, Costa Rica
3
Antimicrobial Stewardship Program, Hospital Clínica Bíblica, San José 10104, Costa Rica
4
Microbiology Department, Hospital Clínica Bíblica, San José 10104, Costa Rica
5
Center for Research in Tropical Diseases (CIET), University of Costa Rica, San José 11501, Costa Rica
6
Faculty of Microbiology, University of Costa Rica, San José 11501, Costa Rica
*
Author to whom correspondence should be addressed.
Bacteria 2023, 2(4), 185-195; https://doi.org/10.3390/bacteria2040014
Submission received: 10 October 2023 / Revised: 20 November 2023 / Accepted: 4 December 2023 / Published: 12 December 2023
Versions Notes

Abstract

:
(1) Background: Given the widespread use of Alkalihalobacillus clausii (A. clausii) as a probiotic in recent decades and the detection of bacteremia cases in a group of patients, we sought to analyze cases of A. clausii bacteremia following oral probiotic use (2) Methods: A retrospective observational study was conducted at a private hospital in San Jose, Costa Rica. Cases of bacteremia caused by A. clausii confirmed by the microbiology laboratory were analyzed in patients who received oral treatment with this probiotic between January 2020 and January 2022. In addition, an isolate (HCB-AC2) was compared through whole genome sequencing to demonstrate the correlation of bacteremia and A. clausii. Possible vulnerability factors related to the development of this condition were determined. (3) Results: Four cases were identified in this hospital over 2 years. Genomic analysis of isolate HCB-AC2, using two different methods, showed identical results. This indicates that HCB-AC2 is genomically identical to ENTpro and the Enterogermina® reference genome. The median age was 71 years, and all patients had some degree of immunosuppression. All patients met at least three sepsis criteria at the time of bacterial identification. Most patients were treated with vancomycin and levofloxacin. Three of the identified patients died. (4) Conclusion: A. clausii can be used as a probiotic, but caution is advised when used in immunosuppressed and elderly patients. These findings align with those reported in similar case studies.

1. Introduction

The Food and Agriculture Organization of the United Nations and the World Health Organization (WHO) defined probiotics as live microorganisms that, when administered in adequate amounts, improve host health [1,2]. In recent decades, there is widespread interest worldwide for commercially available probiotics, not only because of their robust safety profile but also because of the wide range of human health benefits [2]. Actual available products contain bacterial agents such as Lactobacillus spp. [3], Bifidobacterium spp. [3], strains of Saccharomyces cerevisiae, Aspergillus niger, and Bacillus spp. that are common members of the endogenous gut microbiota [4,5].
There is strong evidence supporting the benefits of probiotics predominantly in the treatment of gastrointestinal conditions such as acute gastroenteritis, antibiotic-associated diarrhea, Crohn’s disease, celiac disease, inflammatory bowel disease, and Clostridiodes and Helicobacter pylori infection [6,7,8,9,10,11]. Others under study include constipation, necrotizing enterocolitis and colorectal cancer [2,12,13,14,15]
Over the years, the precise mechanism by which probiotics generate beneficial gastrointestinal effects has been studied [16]. However, multiple pathways have been found by which they exert their effect, and it is suggested that they act through a multifaceted mechanism. Among the reported pathways are the colonization and reestablishment of the intestinal microbiota balance, the competitive exclusion of pathogens through the secretion of antimicrobials such as bacteriocins [17,18], competition for the environment and adherence to the intestinal wall [19,20], improvement of mucin production [19], immunomodulatory effects [21,22], and secretion of short-chain fatty acids [2,5,23].
Probiotics also exhibit nerve, endocrine, anticancer, and metabolic functions [6,21,24,25]. For example, there are reports of decreases in cholesterol levels that have been associated with metabolites of probiotics such as bacteriocins, biosurfactants, exopolysaccharides, and siderophores [4,5]. There is ample evidence to support the notion that probiotics can be considered valuable not only for treating diseases but also for their prevention.
Bacillus spp. strains are aerobic Gram-positive rod-shaped bacteria that form endospores [26], consisting of a core with a condensed and inactive chromosome, and additional layers, including a peptidoglycan-rich cortex [24]. The onset of sporulation occurs when the environment in which the bacterium is located presents a decrease in available nutrients [27]; then, the bacterium initiates the irreversible process to produce spores, which takes approximately 8 h [24,28].
The sporulation process preserves the life of the bacterium through the development of bacterial spores which survive in the long term under extreme environmental and physiological conditions [29,30,31], such as ultraviolet radiation, extreme heat, humidity, and the acidic environment of the stomach and gastrointestinal tract [27]. These properties allow them to be found in nature and in soil, air, foods undergoing fermentation, and the human intestine [24,28].
Currently, there are multiple brands of probiotics containing Alkalihalobacillus clausii (A. clausii), formerly Bacillus clausii, available worldwide [32]. This probiotic is an over-the-counter medicinal supplement and is manufactured in the form of an oral suspension, containing 2 billion or 4 billion spores of this microorganism. It is approved for the treatment and prophylaxis of alterations in intestinal bacterial flora due to endogenous avitaminosis, as well as for the recovery from dysbiosis caused by antibiotic or chemotherapy agents [1,2,11,24,26].
There is substantial proof to back up the therapeutic use of this probiotic around the world [2,11,33]. However, there have been reports questioning its efficacy and safety [33]. Post-marketing, the main potential side effects reported by the WHO include gastrointestinal disorders, general disorders, and conditions at the administration site, skin and subcutaneous tissue disorders, and infections [34].
Upon conducting a comprehensive analysis of various strains of Bacillus spp., including A. clausii, several disadvantages have come to light regarding their suitability as probiotics. These limitations primarily arise from their potential to transmit resistance genes, such as the erm gene responsible for macrolide resistance, and their ability to generate enterotoxins and biogenic amines [35]. Nevertheless, it is essential to acknowledge that different strains of A. clausii, which have also undergone studies, have demonstrated safety profiles and an inability to transfer such genes [5,35]. This underscores the significance of careful strain selection and rigorous testing to ensure the probiotic’s safety and effectiveness.
This study involved a retrospective analysis of the cases of patients with some level of immunosuppression who developed bacteremia following administration of the probiotic A. clausii and were hospitalized in a private hospital in San Jose, Costa Rica. This research aims to comprehensively evaluate the safety of this probiotic and identify its potential associations.

2. Results

Four patients who developed bacteremia following the administration of A. clausii were identified. This microorganism was detected in the hospital’s clinical laboratory using an automated blood culture system; then, it was isolated and identified through a proteomic methodology known as MALDI-TOF.
Table 1 shows the baseline characteristics of the identified patients. The median age was 71 years. The distribution of patients by gender was balanced. All patients had underlying medical conditions, including 75.0% (n = 3) with hypertension (HTA), 50.0% (n = 2) with diabetes mellitus (DM), 50.0% (n = 2) with dyslipidemia, and 25.0% (n = 1) with cancer. Importantly, every patient in this series exhibited some level of immunosuppression.
All patients experienced an adverse drug reaction associated with antibiotic use, specifically a disruption in their bacterial flora, which prompted the prescription of this probiotic. The alteration of the microbiota led to diarrhea in most cases (n = 3), as shown in Table 2. The most used dosage of A. clausii was 4 billion in 75.0% (n = 3) of patients. The median duration of A. clausii treatment before the onset of bacteremia was 9 days (ranging from 4 to 15 days). Additionally, it was observed that three patients continued A. clausii treatment for an average of 1 day after a positive bacteremia culture was detected.
The clinical characteristics of the identified patients are presented in Table 3. Following the use of the SIRS criteria as a method to standardize the potential severe disease associated with A. clausii bacteremia, it was found that all patients had at least three criteria of this scale. The most common signs and symptoms were temperature greater than 38 °C, followed by heart rate greater than 90 beats per minute, and respiratory rate greater than 20 breaths per minute. Among the patient group, renal dysfunction was detected in one of them, along with one case of respiratory dysfunction and another case of hypotension.
The antibiotic therapy used in patients upon the presentation of A. clausii bacteremia was in line with what is found in the literature in 75.0% (n = 3) of the patients. After the detection of bacteremia, three patients passed away, and one patient was discharged, making it impossible to ascertain their outcome. On average 17 days after the detection of A. clausii in the blood culture, the patients died.
Mapping of HCB-AC2 reads to a reference ENTPro genome revealed 21 G or C insertions, with nearly half of them seen in homopolymer G or C stretches, and a 1 bp deletion in the intergenic region upstream of a cat gene encoding a chloramphenicol acetyltransferase (Table 4). Moreover, the HCB-AC2 assembly was identical to a draft genome that we generated in parallel for a bacterial isolate that we cultivated from an Enterogermina® vial (data not shown). The aforementioned variations align with sequencing by synthesis errors. Hence, it is plausible that the ENTPro genome and our Enterogermina® draft genome are the same.

3. Discussion

In this study, we included data from four new cases of patients who developed bacteremia after the administration of A. clausii and were admitted to a single private hospital in the country. Currently, there are only 10 clinical cases of bacteremia attributed to A. clausii (Table 5), which represents a small number of patients. None of these documented cases have demonstrated the correlation between the development of bacteremia and the administration of A. clausii through genetic testing; it has only been reported from microbiological cultures.
This is the first case report to present genetic evidence of the correlation of the development of bacteremia after the initiation of A.clausii therapy in one of the patients. Proof of this is that the HCB-AC2 isolate is genomically indistinguishable from ENTpro and our own Enterogermina® reference genome, except for a few minor changes that we believe to be sequencing artifacts based on previous observations [36].
For the other cases, it was not possible to perform such genomic analysis. However, there is a high probability that this probiotic may translocate from the intestinal tract into the bloodstream, particularly in individuals with specific predisposing factors [34,37,38,39,40,41,42]. This underscores the need for further microbiological and genetic studies in future reports for the detection of risk factors associated with such translocation and their possible clinical implications.
While it is true that the evidence for bacteremia caused by A. clausii is limited, there are at least eight reports in which the association between the development of bacteremia and the use of probiotics such as Lactobacilli, including Lactobacillus acidophilus, Lactobacillus casei, and Lactobacillus GG, has been demonstrated. In addition, there are more than nine cases of sepsis due to Saccharomyces boulardii, Lactobacillus GG [43,44,45,46,47], Bacillus subtilis [48,49], Bifidobacterium breve [50], or a combination of probiotics. Particularly these cases develop in patients with chronic anatomical conditions, patients with some degree of immunosuppression, and patients with intestinal conditions [43,44,45,46,47,48,49,50].
As established by the evidence and in our study, the use of oral probiotics is mainly indicated for the treatment of diarrhea, nausea, and vomiting associated with the use of antibiotics. However, a common problem lies in the use of these in populations considered at high risk due to their level of immunosuppression, whether due to age, high doses of steroids, chronic diseases, cancer treatments, or severe acute illnesses [38,39,51]. In fact, all patients in our study met the criteria for SIRS, and three of them experienced organ dysfunction.
These findings highlight the importance of conducting pharmacovigilance studies of the use of A. clausii as a probiotic. As of now, official safety information regarding this probiotic has not been updated, and there are no established recommendations concerning its utilization in high-risk populations. Furthermore, it is crucial to investigate the potential correlation between A. clausii overdose and the risk of microbial infection, especially considering that one case in this study was prescribed doses exceeding the recommended levels. No existing evidence was found regarding the analysis of dosage effects [5,24,51]. This underscores the need for further research and vigilant oversight to establish safe and effective guidelines for the use of A. clausii as a probiotic, particularly in vulnerable patient populations.
The recommended antibiotics for the treatment of infections caused by A. clausii, which are susceptible to various species of the Bacillus genus, are vancomycin (as the first choice) or clindamycin, with fluoroquinolones or imipenem as alternatives. If the above antibiotics are not available, Linezolid can be used [52,53]. Four of the cases detected in this center received optimal antibiotic treatment. It should be considered that in all patients other microorganisms were detected, so they required more than one antibiotic (Table 3). One case received non-optimal treatment with trimethoprim/sulfamethoxazole (TMP-SMX). The resistance of this antibiotic to Bacillus has been reported in several studies, so its use is not recommended for the management of A. clausii infections [52,53,54].
Table 5. Profile of patients documented with bacteriemia due to A. clausii administration [37,38,40,41,50,53,54].
Table 5. Profile of patients documented with bacteriemia due to A. clausii administration [37,38,40,41,50,53,54].
Age (Years)Patient ProfileTreatmentAntibiotic
Susceptibility		OutcomeAuthorsYear of
Publication		Country
69Ventilator-associated pneumonia, BSA, progresses to acute diarrhea.Vancomycin + Levofloxacin + RifampicinNDRecoveryNacinovich, F. et al.2017 [54]Argentina
71MI, catheter-associated infection, in treatment with BSA evolution for acute diarrhea.Vancomycin + LevofloxacinNDRecoveryNacinovich, F. et al. 2017 [54]Argentina
NDPneumonia and Stage IV lung cancer.NDResistance to clindamycin, penicillin, and tetracycline.DischargeGargar, JD. et al.2019 [37]ND
NDPneumonia and Stage IV lung cancer. NDNDRecoveryGargar, JD. et al.2019 [37]ND
NDSeptic shock from ischemic colitis.NDNDRecoveryGargar, JD. et al.2019 [37]ND
5 monthsCongenital heart disease, recurrent respiratory tract infections, repeated hospital/ICU admissions, BSA.VancomycinSusceptibility to vancomycin and penicillin.DischargeJoshi, S. et al.2019 [41]ND
NDDM 2, with decompressive craniotomy and BSA.TeicoplaninSusceptibility to ciprofloxacin and vancomycin. Penicillin resistant.DischargePrincess et al.2020 [38]India
87HT, EPOC, cholecystectomy, hypertension, urinary tract infection caused by Klebsiella pneumoniae.Vancomycin + CefepimeNDDischargeGarcía, J. et al.2021 [50]Colombia
1 & 5 monthNone. Ceftriaxone, Ampicillin, Levofloxacin, Vancomycin, GentamicinSusceptibility to ceftriaxone, levofloxacin, and vancomycin. Penicillin, rifampin, and clindamycin resistant. RecoveryKhatri, A. et al.2021 [40]United States
37Postoperative bariatric surgery type sleeve, presented thoracoabdominal fistula, treated with BSA evolves to acute diarrhea.VancomycinNDDischargeSchierling, N. et al.2022 [53]Brazil
Abbreviations: BSA: broad-spectrum antibiotics; ND: no documentation; HT: hypertension; MI: myocardial infarction; ICU: intensive care unit.
Due to the small number of bacteremia cases in our study, we cannot calculate mortality rates accurately. However, when reviewing the literature, we found that 5 of the 10 previously reported cases resulted in the death of patients, which seems to indicate a higher mortality than is considered typical for this infection [37,38,51].
Limitations of this analysis should be considered, including the lack of sufficient microbiological analysis to guarantee that the A. clausii isolated from three of the patients is the same as the medication supplied and the absence of antimicrobial susceptibility testing on A. clausii. The results should be interpreted cautiously, and further research with a larger sample size would be necessary to confidently identify and characterize risk factors and clinical complications.

4. Materials and Methods

4.1. Setting and Study Design

A retrospective observational study was carried out at a private hospital located in San Jose, Costa Rica, from January 2020 to January 2022. It analyzed cases of bacteremia caused by A. clausii in adult patients who had undergone treatment with Enterogermina® and Enterogermina® Plus. Patients with incomplete medical records were excluded from the analysis, ensuring the integrity and reliability of the data.

4.2. Data Collection and Outcome Measures

The data were obtained from electronic clinical records of the hospital. This included patient information like age, gender, comorbidities, clinical history, admission details, and admission dates. Additionally, we gathered data on the use of A. clausii, including the reason for use, dosage, and length of treatment. Other collected information included the date of A. clausii detection, the patient’s progress following bacteremia, the outcome, laboratory test results, culture findings, and the antibiotics used to treat the infection.
The systemic inflammatory response syndrome (SIRS) criteria were determined as described previously considering heart rate, respiratory rate, temperature, and leukocyte count and/or presence of bands [55], and organ dysfunction caused by the infection was classified according to the Swedish Society of Infectious Diseases guidelines as described by Senneby et al. [56]. Hypotension was defined as systolic blood pressure <90 mmHg or mean arterial pressure <70 mmHg; respiratory dysfunction was defined as peripheral oxygen saturation <90%; renal dysfunction was defined as an increase in serum creatinine levels of >45 μM, initiation of dialysis or urinary output <0.5 mL/kg/h for >2 h [55,57].

4.3. Bacterial Isolates

Blood was cultured using aerobic and anaerobic media bottles from the automated blood culture system Bactec FX40 (Becton-Dickinson®, Sparks, MD, USA). Positive bottles for the presence of Gram-positive rods were inoculated on Liofilchem® Columbia Agar (Roseto degli Abruzzi, Teramo, Italy) with 5% sheep blood. Plates were incubated for 24 h at 37 °C in an aerobic atmosphere. Finally, isolates were identified using MALDI-TOF mass spectrometry in a Microflex LT/SH (Bruker Daltonics®, Bremen, Germany) in association with the MALDI Biotyper® Version 3.1 software.

4.4. Statistical Analysis

Given the limited sample size in this study, it is not feasible to employ a statistically representative model or conduct inferential analysis to discern specific trends.

4.5. Bioinformatic Analysis

For this analysis, only the HCB-AC2 isolate was available from the processed sample of patient HCB-2. To determine whether HCB-AC2 indeed correspond to the strain included in the probiotic formulation Enterogermina® (Sanofi-Aventis, Paris, France), we mapped Illumina reads that were trimmed with fastp v.023.4 to the chromosomal sequence of B. claussii ENTPro (Genbank CP012475), which were obtained through PacBio sequencing with the P6C4 chemistry [58]. This mapping was performed with the Breseq pipeline for finding mutations in haploid microbial genomes [59], and snippy for core SNP detection [60]. We also generated a whole-genome assembly with skesa for an isolate that we cultivated from a vial of Entergermina® purchased locally (lot 0I065).

4.6. Ethics Approval and Consent to Participate

Ethical approval to conduct this study was obtained from the Scientific Ethical Committee of the University of Medical Sciences (CEC-UCIMED), approval date of 2 June 2021, reference number CEC-632-10-2022, and approval date of 29 November 2022. Written consent was not necessary for this study according to this committee.

4.7. Declaration of Generative AI and AI-Assisted Technologies

During the development of this project, the authors utilized ChatGPT to improve the clarity of translated sentences. Subsequently, after using this tool/service, the authors conducted a thorough review and made any necessary refinements to the content, fully taking responsibility for this publication’s material.

5. Conclusions

A. clausii can indeed function as a probiotic agent; however, it is essential to exercise caution when contemplating its administration to immunosuppressed and elderly individuals. These research findings emphasize the crucial need for personalized medical assessments and customized therapeutic strategies when considering probiotic supplementation for such patients. Healthcare professionals should meticulously balance the potential advantages with potential risks, maintaining vigilant monitoring for any adverse reactions or indications of infection when incorporating A. clausii into patient care plans.

Author Contributions

Conceptualization, J.P.D.-M. and E.Z.-M.; methodology, J.P.D.-M., S.A.-C. and B.S.-A.; software, S.A.-C., C.R. and C.R.-C.; validation, A.F.V.-M., K.S.G.-G. and C.R.; formal analysis, J.P.D.-M., E.Z.-M., S.A.-C. and B.S.-A.; investigation, J.P.D.-M., S.A.-C. and B.S.-A.; resources, M.A.F.-M., B.M.R.-C., P.Z.-A. and K.S.G.-G.; data curation, M.A.F.-M., B.M.R.-C. and P.Z.-A.; writing—original draft preparation, J.P.D.-M., B.S.-A. and C.R.-C.; writing—review and editing, J.P.D.-M.,C.R.-C. and C.R.; visualization, J.P.D.-M. and B.S.-A.; supervision, J.P.D.-M., S.A.-C. and B.S.-A.; project administration, J.P.D.-M., S.A.-C. and C.R.-C. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Scientific Ethical Committee of the University of Medical Sciences (CEC-UCIMED) (protocol code CEC-632-10-2022 and approval date of 29 November 2022).

Informed Consent Statement

Patient consent was waived due to the retrospective, noninterventional design of this study. The confidentiality of all data obtained during the research was guaranteed.

Data Availability Statement

The data are not available due to the confidentiality established in the legislation of this country.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Joint FAO WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food (Ed.) Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation; FAO Food and Nutrition Paper; Food and Agriculture Organization of the United Nations: Rome, Italy, 2006; 50p. [Google Scholar]
  2. Acosta-Rodríguez-Bueno, C.P.; Abreu, Y.; Abreu, A.T.; Guarner, F.; Guno, M.J.V.; Pehlivanoğlu, E.; Perez, M. Bacillus clausii for Gastrointestinal Disorders: A Narrative Literature Review. Adv. Ther. 2022, 39, 4854–4874. [Google Scholar] [CrossRef]
  3. Saarela, M.; Matto, J.; Mattila-Sandholm, T. Safety Aspects of Lactobacillus and Bifidobacterium Species Originating from Human Oro-gastrointestinal Tract or from Probiotic Products. Microb. Ecol. Health Dis. 2002, 14, 234–241. [Google Scholar] [CrossRef]
  4. Enterogermina. Sanofi. Available online: https://www.enterogermina.com.do/-/media/ems/conditions/consumer%20healthcare/brands/enterogermina-cac/prodotto_hp/enterogermina.pdf (accessed on 13 September 2023).
  5. Lee, N.-K.; Kim, W.-S.; Paik, H.-D. Bacillus strains as human probiotics: Characterization, safety, microbiome, and probiotic carrier. Food Sci. Biotechnol. 2019, 28, 1297–1305. [Google Scholar] [CrossRef] [PubMed]
  6. Stavropoulou, E.; Bezirtzoglou, E. Probiotics in Medicine: A Long Debate. Front. Immunol. 2020, 11, 2192. [Google Scholar] [CrossRef]
  7. Vitetta, L.; Briskey, D.; Alford, H.; Hall, S.; Coulson, S. Probiotics, prebiotics and the gastrointestinal tract in health and disease. Inflammopharmacol 2014, 22, 135–154. [Google Scholar] [CrossRef] [PubMed]
  8. Cai, J.; Zhao, C.; Du, Y.; Zhang, Y.; Zhao, M.; Zhao, Q. Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis. UEG J. 2018, 6, 169–180. [Google Scholar] [CrossRef] [PubMed]
  9. Kim, S.-K.; Guevarra, R.B.; Kim, Y.-T.; Kwon, J.; Kim, H.; Cho, J.H.; Kim, H.B.; Lee, J.-H. Role of Probiotics in Human Gut Microbiome-Associated Diseases. J. Microbiol. Biotechnol. 2019, 29, 1335–1340. [Google Scholar] [CrossRef] [PubMed]
  10. Brüssow, H. Probiotics and prebiotics in clinical tests: An update. F1000Research 2019, 8, 1157. [Google Scholar] [CrossRef] [PubMed]
  11. Lopetuso, L.R.; Scaldaferri, F.; Franceschi, F.; Gasbarrini, A. Bacillus clausii and gut homeostasis: State of the art and future perspectives. Expert Rev. Gastroenterol. Hepatol. 2016, 10, 943–948. [Google Scholar] [CrossRef]
  12. Olveira, G.; González-Molero, I. Actualización de probióticos, prebióticos y simbióticos en nutrición clínica. Endocrinol. Nutr. 2016, 63, 482–494. [Google Scholar] [CrossRef]
  13. Zhang, C.; Jiang, J.; Tian, F.; Zhao, J.; Zhang, H.; Zhai, Q.; Chen, W. Meta-analysis of randomized controlled trials of the effects of probiotics on functional constipation in adults. Clin. Nutr. 2020, 39, 2960–2969. [Google Scholar] [CrossRef] [PubMed]
  14. Dimidi, E.; Christodoulides, S.; Fragkos, K.C.; Scott, S.M.; Whelan, K. The effect of probiotics on functional constipation in adults: A systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2014, 100, 1075–1084. [Google Scholar] [CrossRef] [PubMed]
  15. Miller, L.E. Probiotic supplementation decreases intestinal transit time: Meta-analysis of randomized controlled trials. WJG 2013, 19, 4718. [Google Scholar] [CrossRef] [PubMed]
  16. Plaza-Diaz, J.; Ruiz-Ojeda, F.J.; Gil-Campos, M.; Gil, A. Mechanisms of Action of Probiotics. Adv. Nutr. 2019, 10, S49–S66. [Google Scholar] [CrossRef] [PubMed]
  17. Bermudez-Brito, M.; Plaza-Díaz, J.; Muñoz-Quezada, S.; Gómez-Llorente, C.; Gil, A. Probiotic Mechanisms of Action. Ann. Nutr. Metab. 2012, 61, 160–174. [Google Scholar] [CrossRef] [PubMed]
  18. Umu, Ö.C.O.; Rudi, K.; Diep, D.B. Modulation of the gut microbiota by prebiotic fibres and bacteriocins. Microb. Ecol. Health Dis. 2017, 28, 1348886. [Google Scholar] [CrossRef] [PubMed]
  19. Collado, M.C.; Gueimonde, M.; Salminen, S. Probiotics in Adhesion of Pathogens. In Bioactive Foods in Promoting Health; Elsevier: Amsterdam, The Netherlands, 2010; pp. 353–70. Available online: https://linkinghub.elsevier.com/retrieve/pii/B9780123749383000232 (accessed on 20 November 2023).
  20. Plaza-Díaz, J.; Ruiz-Ojeda, F.; Gil-Campos, M.; Gil, A. Immune-Mediated Mechanisms of Action of Probiotics and Synbiotics in Treating Pediatric Intestinal Diseases. Nutrients 2018, 10, 42. [Google Scholar] [CrossRef]
  21. D’Amelio, P.; Sassi, F. Gut Microbiota, Immune System, and Bone. Calcif. Tissue Int. 2018, 102, 415–425. [Google Scholar] [CrossRef]
  22. Gómez-Llorente, C.; Muñoz, S.; Gil, A. Role of Toll-like receptors in the development of immunotolerance mediated by probiotics. Proc. Nutr. Soc. 2010, 69, 381–389. [Google Scholar] [CrossRef]
  23. Lee, N.-K.; Son, S.-H.; Jeon, E.B.; Jung, G.H.; Lee, J.-Y.; Paik, H.-D. The prophylactic effect of probiotic Bacillus polyfermenticus KU3 against cancer cells. J. Funct. Foods 2015, 14, 513–518. [Google Scholar] [CrossRef]
  24. Cutting, S.M. Bacillus probiotics. Food Microbiol. 2011, 28, 214–220. [Google Scholar] [CrossRef] [PubMed]
  25. Kanmani, P.; Satish Kumar, R.; Yuvaraj, N.; Paari, K.A.; Pattukumar, V.; Arul, V. Probiotics and Its Functionally Valuable Products—A Review. Crit. Rev. Food Sci. Nutr. 2013, 53, 641–658. [Google Scholar] [CrossRef] [PubMed]
  26. Elshaghabee, F.M.F.; Rokana, N.; Gulhane, R.D.; Sharma, C.; Panwar, H. Bacillus as Potential Probiotics: Status, Concerns, and Future Perspectives. Front. Microbiol. 2017, 8, 1490. [Google Scholar] [CrossRef]
  27. Cenci, G.; Trotta, F.; Caldini, G. Tolerance to challenges miming gastrointestinal transit by spores and vegetative cells of Bacillus clausii. J. Appl. Microbiol. 2006, 101, 1208–1215. [Google Scholar] [CrossRef]
  28. Fuente, M.D.l. La microbiota. Su función en la fisiología humana. In Fisiología Humana, 5th ed.; Fernández-Tresguerres, J.A., Cachofeiro, V., Cardinali, D.P., Delpón, E., Díaz-Rubio, E.R., Escriche, E.E., Juliá, V.L., Teruel, F.M., Pardo, M.R., Eds.; McGraw-Hill Education: New York, NY, USA, 2020. [Google Scholar]
  29. Nakano, M.M.; Corbell, N.; Besson, J.; Zuber, P. Isolation and characterization of sfp: A gene that functions in the production of the lipopeptide biosurfactant, surfactin, in Bacillus subtilis. Mol. Gen. Genet. 1992, 232, 313–321. [Google Scholar] [CrossRef] [PubMed]
  30. Hoa, T.T.; Duc, L.H.; Isticato, R.; Baccigalupi, L.; Ricca, E.; Van, P.H.; Cutting, S.M. Fate and Dissemination of Bacillus subtilis Spores in a Murine Model. Appl. Environ. Microbiol. 2001, 67, 3819–3823. [Google Scholar] [CrossRef] [PubMed]
  31. Duc, L. Germination of the spore in the gastrointestinal tract provides a novel route for heterologous antigen delivery. Vaccine 2003, 21, 4215–4224. [Google Scholar] [CrossRef]
  32. Patel, S.; Gupta, R.S. A phylogenomic and comparative genomic framework for resolving the polyphyly of the genus Bacillus: Proposal for six new genera of Bacillus species, Peribacillus gen. nov., Cytobacillus gen. nov., Mesobacillus gen. nov., Neobacillus gen. nov., Metabacillus gen. nov. and Alkalihalobacillus gen. nov. Int. J. Syst. Evol. Microbiol. 2020, 70, 406–438. [Google Scholar] [CrossRef]
  33. Sudha, M.R.; Bhonagiri, S.; Kumar, M.A. Efficacy of Bacillus clausii strain UBBC-07 in the treatment of patients suffering from acute diarrhoea. Benef. Microbes 2013, 4, 211–216. [Google Scholar] [CrossRef]
  34. VigiAccess. Available online: https://www.vigiaccess.org/ (accessed on 13 September 2023).
  35. Bozdogan, B.; Galopin, S.; Leclercq, R. Characterization of a New erm-Related Macrolide Resistance Gene Present in Probiotic Strains of Bacillus clausii. Appl. Environ. Microbiol. 2004, 70, 280–284. [Google Scholar] [CrossRef]
  36. Nakamura, K.; Oshima, T.; Morimoto, T.; Ikeda, S.; Yoshikawa, H.; Shiwa, Y.; Ishikawa, S.; Linak, M.C.; Hirai, A.; Takahashi, H.; et al. Sequence-specific error profile of Illumina sequencers. Nucleic Acids Res. 2011, 39, e90. [Google Scholar] [CrossRef]
  37. Gargar, J.D.; Divinagracia, R.M. When good things go bad: A case series of bacteremia from probiotics. Chest 2019, 155, 92A. [Google Scholar] [CrossRef]
  38. Princess, I.; Natarajan, T.; Ghosh, S. When good bacteria behave badly: A case report of Bacillus clausii sepsis in an immuno-competant adult. Access Microbiol. 2020, 2, e000097. [Google Scholar] [CrossRef] [PubMed]
  39. Fernandez Oses, P.; Galizia Brito, V.; Sucari, A.; Peninni, M.; Gentiluomo, J.; Merkt, M.; Castillo, S.; Zanella, M.; Place, P.; Ramirez, S.; et al. Bacteremia por Bacillus clausii Asociada a la Administración de Probióticos. In Proceedings of the XVII Congreso Sociedad Argentina de Infectología (SADI), Mar del Plata, Argentina, 15–17 June 2017. [Google Scholar]
  40. Khatri, A.M.; Rai, S.; Shank, C.; McInerney, A.; Kaplan, B.; Hagmann, S.H.F.; Kainth, M.K. A tale of caution: Prolonged Bacillus clausii bacteraemia after probiotic use in an immunocompetent child. Access Microbiol. 2021, 3, 000205. Available online: https://www.microbiologyresearch.org/content/journal/acmi/10.1099/acmi.0.000205 (accessed on 14 September 2023). [CrossRef]
  41. Joshi, S.; Udani, S.; Sen, S.; Kirolikar, S.; Shetty, A. Bacillus clausii Septicemia in a Pediatric Patient After Treatment with Pro-biotics. Pediatr. Infect. Dis. J. 2019, 38, e228–e230. [Google Scholar] [CrossRef]
  42. Farina, C.; Arosio, M.; Mangia, M.; Moioli, F. Lactobacillus casei subsp. rhamnosus Sepsis in a Patient With Ulcerative Colitis. J. Clin. Gastroenterol. 2001, 33, 251. [Google Scholar]
  43. Husni, R.N.; Gordon, S.M.; Washington, J.A.; Longworth, D.L. Lactobacillus Bacteremia and Endocarditis: Review of 45 Cases. Clin. Infect. Dis. 1997, 25, 1048–1054. [Google Scholar] [CrossRef] [PubMed]
  44. Kunz, A.N.; Noel, J.M.; Fairchok, M.P. Two Cases of Lactobacillus Bacteremia During Probiotic Treatment of Short Gut Syn-drome. J. Pediatr. Gastroenterol. Nutr. 2004, 38, 457. [Google Scholar] [CrossRef] [PubMed]
  45. Salminen, M.K.; Rautelin, H.; Tynkkynen, S.; Poussa, T.; Saxelin, M.; Valtonen, V.; Järvinen, A. Lactobacillus Bacteremia, Clinical Significance, and Patient Outcome, with Special Focus on Probiotic L. rhamnosus GG. Clin. Infect. Dis. 2004, 38, 62–69. [Google Scholar] [CrossRef]
  46. Salminen, M.K.; Tynkkynen, S.; Rautelin, H.; Saxelin, M.; Vaara, M.; Ruutu, P.; Sarna, S.; Valtonen, V.; Järvinen, A. Lactobacillus Bacteremia during a Rapid Increase in Probiotic Use of Lactobacillus rhamnosus GG in Finland. Clin. Infect. Dis. 2002, 35, 1155–1160. [Google Scholar] [CrossRef]
  47. Oggioni, M.R.; Pozzi, G.; Valensin, P.E.; Galieni, P.; Bigazzi, C. Recurrent Septicemia in an Immunocompromised Patient Due to Probiotic Strains of Bacillus subtilis. J. Clin. Microbiol. 1998, 36, 325–326. [Google Scholar] [CrossRef] [PubMed]
  48. Richard, V.; Auwera, P.; Snoeck, R.; Daneau, D.; Meunier, F. Nosocomial bacteremia caused by Bacillus species. Eur. J. Clin. Microbiol. Infect. Dis. 1988, 7, 783–785. [Google Scholar] [CrossRef] [PubMed]
  49. Ohishi, A.; Takahashi, S.; Ito, Y.; Ohishi, Y.; Tsukamoto, K.; Nanba, Y.; Ito, N.; Kakiuchi, S.; Saitoh, A.; Morotomi, M.; et al. Bifidobacterium Septicemia Associated with Postoperative Probiotic Therapy in a Neonate with Omphalocele. J. Pediatr. 2010, 156, 679–681. [Google Scholar] [CrossRef] [PubMed]
  50. García, J.P.; Alzate, J.A.; Hoyos, J.A.; Cristancho, E. Bacteremia after Bacillus clausii administration for the treatment of acute diarrhea: A case report. Biomedica 2021, 41 (Suppl. 2), 13–20. [Google Scholar] [CrossRef] [PubMed]
  51. Luna, V.A.; King, D.S.; Gulledge, J.; Cannons, A.C.; Amuso, P.T.; Cattani, J. Susceptibility of Bacillus anthracis, Bacillus cereus, Bacillus mycoides, Bacillus pseudomycoides and Bacillus thuringiensis to 24 antimicrobials using Sensititre(R) automated microbroth dilution and Etest(R) agar gradient diffusion methods. J. Antimicrob. Chemother. 2007, 60, 555–567. [Google Scholar] [CrossRef]
  52. Veysseyre, F.; Fourcade, C.; Lavigne, J.-P.; Sotto, A. Bacillus cereus infection: 57 case patients and a literature review. Méd. Mal. Infect. 2015, 45, 436–440. [Google Scholar] [CrossRef]
  53. Schierling, N.L.B.; Silva, A.H.C.d.S.; Pinto, M.R.; Campos, C.M.; Hauki, M.C.; Figueiredo, A.L.; Pedroso, F.P. Bacteremia por Bacillus clausii em paciente imunocompetente: Um relato de caso. Braz. J. Infect. Dis. 2022, 26, 207. [Google Scholar] [CrossRef]
  54. Nacinovich, F.; Fernández, O.; Sucari, A. Probiotics in the Critically Ill: Friends or Foes? Persistent Bacteriemia Due to Bacillus clausii. In Proceedings of the 29th European Congress of Clinical Microbiology & Infectious Diseases, Amsterdam, The Netherlands, 13–16 April 2019. [Google Scholar]
  55. Bone, R.C.; Balk, R.A.; Cerra, F.B.; Dellinger, R.P.; Fein, A.M.; Knaus, W.A.; Schein, R.M.H.; Sibbald, W.J. Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis. Chest 1992, 101, 1644–1655. [Google Scholar] [CrossRef]
  56. Senneby, E.; Petersson, A.C.; Rasmussen, M. Clinical and microbiological features of bacteraemia with Aerococcus urinae. Clin. Microbiol. Infect. 2012, 18, 546–550. [Google Scholar] [CrossRef] [PubMed]
  57. Mellhammar, L.; Linder, A.; Tverring, J.; Christensson, B.; Boyd, J.H.; Sendi, P.; Åkesson, P.; Kahn, F. NEWS2 is Superior to qSOFA in Detecting Sepsis with Organ Dysfunction in the Emergency Department. J. Clin. Med. 2019, 8, 1128. [Google Scholar] [CrossRef]
  58. Khatri, I.; Sharma, G.; Subramanian, S. Composite genome sequence of Bacillus clausii, a probiotic commercially available as Enterogermina®, and insights into its probiotic properties. BMC Microbiol. 2019, 19, 307. [Google Scholar] [CrossRef] [PubMed]
  59. Deatherage, D.E.; Barrick, J.E. Identification of Mutations in Laboratory-Evolved Microbes from Next-Generation Sequencing Data Using breseq. In Engineering and Analyzing Multicellular Systems; Sun, L., Shou, W., Eds.; Methods in Molecular Biology; Springer: New York, NY, USA, 2014; Volume 1151, pp. 165–188. ISBN 978-1-4939-0553-9. Available online: https://link.springer.com/10.1007/978-1-4939-0554-6_12 (accessed on 16 November 2023).
  60. Seemann, T. Snippy. 2023. Available online: https://github.com/tseemann/snippy (accessed on 16 November 2023).
Table 1. Baseline characteristics of the 6 patients with detection of A. clausii in the bloodstream.
Table 1. Baseline characteristics of the 6 patients with detection of A. clausii in the bloodstream.
CaseAge/GenderComorbiditiesPatient ProfilesAdmission
HCB-AC173/MHTA, DLP, DMBacterial pneumonia and SARS-CoV-2COVID-19
HCB-AC239/FAsthmaCardiogenic shock, septic shock, and intrahepatic cholangiocarcinomaLeft intrahepatic cholangiocarcinoma
HCB-AC393/MBasal cell carcinoma, sternal metastasis, HTA, SVTBacterial pneumonia, mechanical ventilationThoracoabdominal dissociation and pleural effusion
HCB-AC478/FHTA, DLP, DM, CVDAspiration pneumoniaPacemaker placement
Abbreviations: DLP: dyslipidemia, HTA: hypertension, DM: diabetes mellitus, Ca: cancer, BPH: benign prostate hyperplasia, UTI: urinary tract infection, Fa: atrial fibrillation, M: male, F: female, SVT: supraventricular tachycardia, CVD: cardiovascular disease.
Table 2. A. clausii administration parameters and time to bacteremia development.
Table 2. A. clausii administration parameters and time to bacteremia development.
CaseA. clausii AdministrationTime to the Onset of
Bacteremia (Days)
Disruptions in
Bacterial Microbiota		Dosage (Billion IU)Duration (Days)
HCB-AC1Diarrhea4 every 12 h76
HCB-AC2Diarrhea, vomiting, and nausea2 every 8 h44
HCB-AC3Diarrhea4 every 24 h98
HCB-AC4Nausea4 every 12 h1520
Abbreviations: IU: international units.
Table 3. Clinical characteristics, treatment, and outcome of patients with A. clausii bacteremia.
Table 3. Clinical characteristics, treatment, and outcome of patients with A. clausii bacteremia.
CaseSIRS CriteriaOrganic
Dysfunction		EvolutionAntibiotic TreatmentOther
Culture Findings		In-Hospital Fatality and Other Remarks
HCB-AC14/4RespPulmonary necrosis, ICU, MV, neurological disorders, upper gastrointestinal bleeding, septic shock.Cefotaxime, LevofloxacinBlood culture: Pseudomonas aeruginosa,
Staphylococos epidermidis.		Died
HCB-AC23/4HTPeritonitis, cardiac arrhythmias, bacteremia, hemodynamic instability.VancomycinPeritoneal fluid: Candida tropicalis, Pseudomonas aeruginosa, Enterococcus faecalis,
Ochrobactrum anthropic.		Died
HCB-AC33/4-Hemodynamic instability, acute renal failure, pneumonia due to superinfection.Ceftazidime- Avibactam +
Vancomycin		Bronchial secretion: Burkholderia cepacian group.Transfer to another hospital
HCB-AC43/4RenHemodynamic instability, cardiac arrhythmias, pneumonia due to superinfection, neurological disorders. Ampicillin+ Levofloxacin
+ TMP-SMX		Bronchial secretion: Stenotrophomonas maltophilia, Escherichia coli, C. albicans.Died
Abbreviations: Res: respiratory dysfunction; HT: hypotension; Ren: renal dysfunction. The comma (,) means a change of antibiotic. The plus sign (+) means multiple antibiotic therapy.
Table 4. Mapping of Illumina reads obtained for HCB-AC2 to a long-read based reference genome (A. clausii ENTPro).
Table 4. Mapping of Illumina reads obtained for HCB-AC2 to a long-read based reference genome (A. clausii ENTPro).
PositionMutationAnnotationGeneDescription
246,999+Gcoding (1215/1416 nt)DB29_00287 ←Membrane protein, putative
505,267(C)5→6coding (137/204 nt)DB29_00564 ←hypothetical protein
670,059(C)8→9intergenic (+16/+23)DB29_00722 →/← DB29_00723Putative glycoside hydrolase/Stage V sporulation protein B
912.77(C)6→7coding (406/459 nt)DB29_00956 ←Phosphoribosylformylglycinamidine cyclo-ligase
1,607,340(C)6→7intergenic (−783/+1)DB29_01660 ←/← DB29_01661putative rhamnogalacturonan lyase in rhamnose utilization cluster/hypothetical protein
1,738,248+Gcoding (269/330 nt)DB29_01784 →Integral membrane protein
1,767,258+Ccoding (754/2934 nt)DB29_01815 ←hypothetical protein
1,810,315+Ccoding (338/483 nt)DB29_01851 ←KinB signaling pathway activation protein
2,359,157(G)5→6coding (557/609 nt)DB29_02403 →Transposase
2,826,475+Ccoding (574/618 nt)DB29_02867 ←TetR family transcriptional regulator
3,061,533+Gintergenic (+94/+14)DB29_03110 →/← DB29_03111Teichuronic acid biosynthesis glycosyl transferase TuaC/hypothetical protein
3,265,972+Cintergenic (−12/+157)DB29_03326 ←/← DB29_03327Isocitrate lyase/hypothetical protein
3,481,536(G)5→6coding (743/828 nt)DB29_03557 →Hypothetical protein
3,528,009+Cintergenic (−11/+264)DB29_03604 ←/← DB29_03605Cytochrome c-type biogenesis protein DsbD, protein-disulfide reductase/hypothetical protein
3,552,355+Gcoding (745/750 nt)DB29_03624 →Uroporphyrinogen-III synthase
3,648,617(G)6→7coding (392/408 nt)DB29_03715 ←Hypothetical protein
3,888,513+Gcoding (3166/3186 nt)DB29_03977 →Chromosome partition protein smc
3,998,002(G)6→7coding (380/468 nt)DB29_04092 →DNA mismatch repair protein MutL
4,192,551(C)5→6coding (2671/2835 nt)DB29_04308 ←Multimodular transpeptidase-transglycosylase
4,259,750(A)7→6coding (532/540 nt)DB29_04378 ←Flagellar motor rotation protein MotB
4,263,161+Gintergenic (−198/−156)DB29_04381 ←/→ DB29_04382Hypothetical protein/hypothetical protein
4,264,808Δ1 bpintergenic (+35/−)DB29_04384 →/–Chloramphenicol acetyltransferase/–
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Díaz-Madriz, J.P.; Zavaleta-Monestel, E.; Rojas-Chinchilla, C.; Arguedas-Chacón, S.; Serrano-Arias, B.; Ferreto-Meza, M.A.; Romero-Chavarría, B.M.; Zumbado-Amerling, P.; Vásquez-Mendoza, A.F.; Gutiérrez-González, K.S.; et al. Bacteremia Following Alkalihalobacillus clausii (Formerly Bacillus clausii) Administration in Immunosuppressed Adults: A Case Series. Bacteria 2023, 2, 185-195. https://doi.org/10.3390/bacteria2040014

AMA Style

Díaz-Madriz JP, Zavaleta-Monestel E, Rojas-Chinchilla C, Arguedas-Chacón S, Serrano-Arias B, Ferreto-Meza MA, Romero-Chavarría BM, Zumbado-Amerling P, Vásquez-Mendoza AF, Gutiérrez-González KS, et al. Bacteremia Following Alkalihalobacillus clausii (Formerly Bacillus clausii) Administration in Immunosuppressed Adults: A Case Series. Bacteria. 2023; 2(4):185-195. https://doi.org/10.3390/bacteria2040014

Chicago/Turabian Style

Díaz-Madriz, José Pablo, Esteban Zavaleta-Monestel, Carolina Rojas-Chinchilla, Sebastián Arguedas-Chacón, Bruno Serrano-Arias, Mery Alejandra Ferreto-Meza, Betzy María Romero-Chavarría, Priscila Zumbado-Amerling, Ana Fernanda Vásquez-Mendoza, Karla Sofia Gutiérrez-González, and et al. 2023. "Bacteremia Following Alkalihalobacillus clausii (Formerly Bacillus clausii) Administration in Immunosuppressed Adults: A Case Series" Bacteria 2, no. 4: 185-195. https://doi.org/10.3390/bacteria2040014

Article Metrics

Back to TopTop